NeuroMedix

NeuroMedix was a clinical-stage biopharmaceutical company that specialized in the development of treatments for neurodegenerative and inflammatory diseases, with a specific focus on Alzheimer's disease and Amyotrophic Lateral Sclerosis (ALS). The company's therapeutic approach utilized nitric oxide-releasing technology to create safer and more effective versions of established drugs, such as its lead candidate NMX-171, a nitric oxide-donating derivative of flurbiprofen. By incorporating a nitric oxide moiety, the company aimed to reduce the gastrointestinal and systemic side effects of NSAIDs while potentially enhancing neuroprotective effects. Although NeuroMedix advanced its lead programs into Phase 2 clinical trials and was publicly traded, the company eventually ceased its development activities and is currently inactive.